Remimazolam in pediatric anesthesia: a systematic review for clinical decision-making
Frontiers in Pediatrics · 23.09.2025 · 13
DOI: 10.3389/fped.2025.1662752 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pediatrics, online erschienen am 23.09.2025. Verfasst von Yi Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Maternal and Child Health Hospital of Wanzhou District, Chongqing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Remimazolam's role in pediatric anesthesia is evolving. We systematically reviewed 2024–2025 evidence to establish a clinical decision-making framework for its use.
Methods
Following PRISMA guidelines, a systematic search identified 23 studies (15 RCTs) involving 2,847 pediatric patients for narrative synthesis.
Results
Remimazolam demonstrated superior hemodynamic stability vs. propofol (cardiovascular complications: RR 0.30, 95% CI 0.20–0.46) and reduced emergence delirium by 61% (RR 0.39, 95% CI 0.21–0.70). The CES1 G143E polymorphism was identified as a genetic basis for prolonged sedation, reducing drug clearance >90%. Critical limitations include a 15% re-sedation rate post-flumazenil, a complete lack of data in infants <1 year, and unknown long-term neurodevelopmental safety.
Conclusion
Remimazolam represents a valuable anesthetic tool with specific advantages in pediatric anesthesia. While it demonstrates superior hemodynamic stability and reduced emergence delirium compared to standard agents, it is not a universal replacement for established anesthetics. Current evidence supports its use in specific clinical scenarios, particularly for preventing post-sevoflurane emergence delirium and in hemodynamically unstable patients. However, the absence of infant and long-term neurodevelopmental safety data necessitates continued research before widespread adoption. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251058023, PROSPERO CRD420251058023 .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology, Maternal and Child Health Hospital of Wanzhou District, Chongqing, China.
- Department of Anesthesiology, People's Hospital of Fengjie, Chongqing, China.
- Department of Nursing, Maternal and Child Health Hospital of Wanzhou District, Chongqing, China.
- Department of Pediatrics, Maternal and Child Health Hospital of Wanzhou District, Chongqing, China.
Zitieren
APA
Zhang, Y., Chen, Q., Wang, L., Zeng, Q., Cui, H., Guo, S., Xiang, F., & Mo, Y. (2025). Remimazolam in pediatric anesthesia: a systematic review for clinical decision-making. Frontiers in Pediatrics, 13. https://doi.org/10.3389/fped.2025.1662752
Vancouver
Zhang Y, Chen Q, Wang L, Zeng Q, Cui H, Guo S, et al. Remimazolam in pediatric anesthesia: a systematic review for clinical decision-making. Frontiers in Pediatrics. 2025;13. doi:10.3389/fped.2025.1662752
BibTeX
@article{Zhang2025,
author = {Zhang, Yi and Chen, Qiuxiang and Wang, Linyun and Zeng, Qingjun and Cui, Haishan and Guo, Shuang and Xiang, Fei and Mo, Yunbo},
title = {Remimazolam in pediatric anesthesia: a systematic review for clinical decision-making},
journal = {Frontiers in Pediatrics},
year = {2025},
volume = {13},
doi = {10.3389/fped.2025.1662752}
}
EUVIMED